Cargando…
Outcomes of a drug shortage requiring switching in patients with ulcerative colitis
BACKGROUND: Drug shortages are common yet their impact on patient care and their commercial ramifications has not been adequately researched. In Australia a shortage of balsalazide (2012-2013) necessitated substitution with alternative 5-aminosalicylate (5-ASA) formulations for ulcerative colitis (U...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156848/ https://www.ncbi.nlm.nih.gov/pubmed/32318313 http://dx.doi.org/10.4291/wjgp.v11.i2.32 |
_version_ | 1783522300011741184 |
---|---|
author | van Langenberg, Daniel R Cheng, Richard Kai-Yuan Garg, Mayur |
author_facet | van Langenberg, Daniel R Cheng, Richard Kai-Yuan Garg, Mayur |
author_sort | van Langenberg, Daniel R |
collection | PubMed |
description | BACKGROUND: Drug shortages are common yet their impact on patient care and their commercial ramifications has not been adequately researched. In Australia a shortage of balsalazide (2012-2013) necessitated substitution with alternative 5-aminosalicylate (5-ASA) formulations for ulcerative colitis (UC). AIM: To assess and compare the clinical and commercial sequelae of non-medical switching from balsalazide to another 5-ASA and/or return to balsalazide once supply resumed. METHODS: A prospective cohort study of patients on balsalazide for mild-moderate UC was conducted where, strictly due to the national shortage (November 2012- January 2013), were switched to alternative 5-ASA and/or then returned to balsalazide once supply resumed. Clinical (Partial Mayo), endoscopic (Mayo score) activity, adverse effects (to alternative 5-ASA) and percentage market share (of continuous 5-ASA users) from baseline (i.e., time of switching due to shortage) through to five years were assessed. RESULTS: Of 31 patients switched due to the shortage, 12 (38.7%) resumed balsalazide immediately once supply resumed, 8 (25.8%) prompted by adverse effects to the alternative 5-ASA used. Three patients (9.7%) had documented symptomatic improvement, 15 (48.4%) were unchanged and 13 (41.9%) had symptomatic worsening vs baseline (P < 0.01), after switching to an alternative 5-ASA. At 3 and 5y post switch, overall 26/31 (83.9%) and 23/31 (74.2%) had remained continuously on any 5-ASA therapy respectively. Twelve (38.7%) and 11 (35.5%) patients remained on balsalazide continuously at three and five years respectively after drug supply returned, equating to a loss of market share (within 5-ASA class) of 45.2% and 38.7% respectively. CONCLUSION: This study of a balsalazide shortage in UC patients exemplifies the detrimental impact of a drug shortage on long term patient, disease and commercial outcomes. |
format | Online Article Text |
id | pubmed-7156848 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-71568482020-04-21 Outcomes of a drug shortage requiring switching in patients with ulcerative colitis van Langenberg, Daniel R Cheng, Richard Kai-Yuan Garg, Mayur World J Gastrointest Pathophysiol Observational Study BACKGROUND: Drug shortages are common yet their impact on patient care and their commercial ramifications has not been adequately researched. In Australia a shortage of balsalazide (2012-2013) necessitated substitution with alternative 5-aminosalicylate (5-ASA) formulations for ulcerative colitis (UC). AIM: To assess and compare the clinical and commercial sequelae of non-medical switching from balsalazide to another 5-ASA and/or return to balsalazide once supply resumed. METHODS: A prospective cohort study of patients on balsalazide for mild-moderate UC was conducted where, strictly due to the national shortage (November 2012- January 2013), were switched to alternative 5-ASA and/or then returned to balsalazide once supply resumed. Clinical (Partial Mayo), endoscopic (Mayo score) activity, adverse effects (to alternative 5-ASA) and percentage market share (of continuous 5-ASA users) from baseline (i.e., time of switching due to shortage) through to five years were assessed. RESULTS: Of 31 patients switched due to the shortage, 12 (38.7%) resumed balsalazide immediately once supply resumed, 8 (25.8%) prompted by adverse effects to the alternative 5-ASA used. Three patients (9.7%) had documented symptomatic improvement, 15 (48.4%) were unchanged and 13 (41.9%) had symptomatic worsening vs baseline (P < 0.01), after switching to an alternative 5-ASA. At 3 and 5y post switch, overall 26/31 (83.9%) and 23/31 (74.2%) had remained continuously on any 5-ASA therapy respectively. Twelve (38.7%) and 11 (35.5%) patients remained on balsalazide continuously at three and five years respectively after drug supply returned, equating to a loss of market share (within 5-ASA class) of 45.2% and 38.7% respectively. CONCLUSION: This study of a balsalazide shortage in UC patients exemplifies the detrimental impact of a drug shortage on long term patient, disease and commercial outcomes. Baishideng Publishing Group Inc 2020-04-12 2020-04-12 /pmc/articles/PMC7156848/ /pubmed/32318313 http://dx.doi.org/10.4291/wjgp.v11.i2.32 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Observational Study van Langenberg, Daniel R Cheng, Richard Kai-Yuan Garg, Mayur Outcomes of a drug shortage requiring switching in patients with ulcerative colitis |
title | Outcomes of a drug shortage requiring switching in patients with ulcerative colitis |
title_full | Outcomes of a drug shortage requiring switching in patients with ulcerative colitis |
title_fullStr | Outcomes of a drug shortage requiring switching in patients with ulcerative colitis |
title_full_unstemmed | Outcomes of a drug shortage requiring switching in patients with ulcerative colitis |
title_short | Outcomes of a drug shortage requiring switching in patients with ulcerative colitis |
title_sort | outcomes of a drug shortage requiring switching in patients with ulcerative colitis |
topic | Observational Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156848/ https://www.ncbi.nlm.nih.gov/pubmed/32318313 http://dx.doi.org/10.4291/wjgp.v11.i2.32 |
work_keys_str_mv | AT vanlangenbergdanielr outcomesofadrugshortagerequiringswitchinginpatientswithulcerativecolitis AT chengrichardkaiyuan outcomesofadrugshortagerequiringswitchinginpatientswithulcerativecolitis AT gargmayur outcomesofadrugshortagerequiringswitchinginpatientswithulcerativecolitis |